Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Up 100.8% in October

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the target of a large growth in short interest in October. As of October 15th, there was short interest totalling 118,900 shares, a growth of 100.8% from the September 30th total of 59,200 shares. Based on an average daily trading volume, of 434,700 shares, the days-to-cover ratio is presently 0.3 days.

Helius Medical Technologies Stock Down 8.8 %

NASDAQ HSDT traded down $0.05 on Friday, reaching $0.49. 62,662 shares of the stock traded hands, compared to its average volume of 770,371. The firm’s fifty day simple moving average is $0.68 and its 200 day simple moving average is $1.36. The company has a market cap of $1.76 million, a price-to-earnings ratio of -0.05 and a beta of 1.60. Helius Medical Technologies has a 12 month low of $0.37 and a 12 month high of $9.50.

Helius Medical Technologies (NASDAQ:HSDT) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.14). The firm had revenue of $0.18 million for the quarter. Helius Medical Technologies had a negative net margin of 1,487.54% and a negative return on equity of 258.06%. During the same period in the prior year, the firm posted ($3.00) earnings per share.

Hedge Funds Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC purchased a new stake in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies as of its most recent filing with the SEC. 18.63% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of Helius Medical Technologies in a report on Wednesday, October 16th.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.